Labs that run molecular diagnostic tests are not only worried about getting short-changed on payment for the tests by some Medicare Part B contractors, but that the tests will not be covered at all.
“A growing concern to us I think, or of equal concern with the prices, is the coverage issue,” JoAnne Glisson, senior VP of the American Clinical Laboratory Association told “The Gray Sheet.” The labs also have outstanding questions about the transparency of Medicare contractors’ system for setting payment rates